U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H19NO3
Molecular Weight 237.2949
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VILOXAZINE

SMILES

CCOC1=C(OCC2CNCCO2)C=CC=C1

InChI

InChIKey=YWPHCCPCQOJSGZ-UHFFFAOYSA-N
InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3

HIDE SMILES / InChI

Description

Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.

Approval Year

2021
478
Targets

Targets

Primary TargetPharmacologyConditionPotency
Sodium-dependent noradrenaline transporter
38
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
Inhibitor
8228
Sodium-dependent noradrenaline transporter
38
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
Inhibitor
8228
PubMed

PubMed

TitleDatePubMed
[Comparative evaluation of the therapeutic efficacy of the antidepressants adepren, linamiphen and emovit].
1986
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.
2002
Simultaneous determination of viloxazine, venlafaxine, imipramine, desipramine, sertraline, and amoxapine in whole blood: comparison of two extraction/cleanup procedures for capillary gas chromatography with nitrogen-phosphorus detection.
2002 Jul-Aug
Contribution of sleep research to the development of new antidepressants.
2005
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.
2005
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
2005 Dec 9
Internet-based search of randomised trials relevant to mental health originating in the Arab world.
2005 Jul 26
Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?
2005 Mar
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach.
2006 Oct 20
Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma.
2007 Dec 28
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood.
2007 May
Adjustment Disorder: epidemiology, diagnosis and treatment.
2009 Jun 26
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.
2009 Nov
Getting the balance right: Established and emerging therapies for major depressive disorders.
2010 Sep 7
Patents

Patents

JP2006516976A
30

Sample Use Guides

In Vivo Use Guide
100 mg
Route of Administration: Oral
Name Type Language
VILOXAZINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
viloxazine [INN]
Common Name English
Viloxazine [WHO-DD]
Common Name English
VILOXAZINE [MI]
Common Name English
MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-
Systematic Name English
(±)-2-(O-ETHOXYPHENOXYMETHYL)MORPHOLINE
Common Name English
VILOXAZIN
Common Name English
VILOXAZINE [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC N06AX09
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
WHO-VATC QN06AX09
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
WIKIPEDIA Designer-drugs-Viloxazine
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
NCI_THESAURUS C265
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
Code System Code Type Description
DAILYMED
5I5Y2789ZF
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
FDA UNII
5I5Y2789ZF
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
MERCK INDEX
M11448
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY Merck Index
INN
3489
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
DRUG BANK
DB09185
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
ChEMBL
CHEMBL306700
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
WIKIPEDIA
VILOXAZINE
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
ECHA (EC/EINECS)
256-281-7
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
EPA CompTox
DTXSID6057900
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
MESH
D014745
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
CAS
46817-91-8
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
RXCUI
11196
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY RxNorm
DRUG CENTRAL
2820
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
PUBCHEM
5666
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
SMS_ID
100000079104
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
EVMPD
SUB00049MIG
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
NCI_THESAURUS
C152877
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of VILOXAZINE
METABOLITE (PARENT)
Structure of 5-HYDROXYVILOXAZINE
METABOLITE INACTIVE (PARENT)
Structure of 5-HYDROXYVILOXAZINE GLUCURONIDE
SALT/SOLVATE (PARENT)
Structure of VILOXAZINE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966